AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04644536 — intervention group
Intervention type: DEVICE
Intervention: Bone graft substitute
Description: Orthopaedic or Spine bony defects
Study NCT02909257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Same Bupivacaine Concentration
Description: patient is exposed to the same concentration than previously successful one
Study NCT02909257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lower Bupivacaine Concentration
Description: patient is exposed to a lower concentration than previously successful one
Study NCT01879878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum, broccoli sprout grain
Description: Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.
Study NCT01879878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution as the experimental arm.
Study NCT02782182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)
Description: FOLFIRINOX administered preoperatively and postoperatively
Study NCT01281761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab/irinotecan/simvastatin
Description: D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- \[C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min\] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV \[over 90min\] D1-14 Simvastatin 80mg P.O(continuous, daily) every 2weeks
Study NCT03139279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.3 ug/kg intravenous bolus
Study NCT03139279 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Intravenous saline/placebo
Study NCT03139279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol titrated intravenous boluses
Study NCT03139279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol titrated intravenous boluses
Study NCT03925246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (Opdivo) is a potent human monoclonal antibody (mAb) of the IgG4 isotype designed to directly block the interaction between Programmed Cell Death 1 (PD-1) and its ligands, Programmed Death Ligand 1 (PD-L1) and PD-L2.~Nivolumab is administered by a 30 minutes intravenous infusion at dose of 240 mg every 2 (+/- 2 days) weeks for 8 cycles (4 months), followed by a dose of 480 mg administered by a 60 minutes intravenous infusion every 4 weeks (+/-3 days) (beginning at cycle 9) for a total therapy duration of 1 year (maximum 16 cycles of treatment) or until progression, death, unacceptable toxicity.
Study NCT04246749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-CRN00808
Description: Investigational drug
Study NCT04246749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN00808
Description: Investigational drug
Study NCT03773562 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erenumab
Description: Erenumab will be used per label instructions.
Study NCT05214508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: interleukin 6
Description: assessment of serum IL-6 by ELISA
Study NCT00745667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic surgery
Description: laparoscopic correction perforated peptic ulcer
Study NCT00745667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper laparotomy
Description: upper laparotomy for correction of perforated peptic ulcer
Study NCT04679987 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Holter ECG
Description: all patients will be monitored for paroxysmal Af by holder ECG
Study NCT00567229 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00567229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Study NCT00567229 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Study NCT00567229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Study NCT00567229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT01522872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Study NCT01522872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 and Dexamethasone
Study NCT01522872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib
Study NCT01522872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide
Study NCT04190173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: 1-2 mg once daily enteral feeding for 5 consecutive days
Study NCT04190173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1/2-1 tablet once daily enteral feeding for 5 consecutive days
Study NCT03857035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Piezosurgery group
Description: Piezosurgery technique will be examined about impacted third molar surgery.
Study NCT03857035 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Piezosurgery group
Description: Piezosurgery technique will be examined about impacted third molar surgery.
Study NCT02562703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
Study NCT02562703 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
Study NCT02954562 — intervention group
Intervention type: OTHER
Intervention: fMRI
Description: Participants will undergo two to three fMRI scans
Study NCT04407052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double trigger
Description: Final follicular maturation is triggered by the coadministration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
Study NCT04407052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG trigger
Description: Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
Study NCT02612038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory resistance
Description: Generic expiratory resistance will be added to the patient's respiratory circuit
Study NCT02612038 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham expiratory resistance
Description: Sham expiratory resistance will be added to the patient's respiratory circuit
Study NCT02993718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: As a loading dose, 0.5 μg/kg dexmedetomidine was administered over 10 min, which was then administered continuously at a dose of 0.2-0.8 μg/kg/h. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
Study NCT02993718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol was infused continuously via a target-controlled infusion device, and the effect-site concentration was maintained with a range of 0.5-2.0 μg/ml. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
Study NCT02607722 — intervention group
Intervention type: DRUG
Intervention: Nintedanib
Study NCT02273531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER, new formulation
Study NCT02273531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asasantin ER, present commercial formulation
Study NCT02603497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral
Study NCT04474301 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT01854762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: a raltegravir-based antiretroviral regimen (AZT+3TC+Raltegravir) will be administered for intervention arm patients (AZT+3TC will be administered in a fixed combination of AZT 300mg +3TC 150 mg, BID. Raltegravir will be administered in a dosis of 1 400 mg pill BID).
Study NCT01854762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: The second arm (comparator)patients will use a regimen composed by AZT+3TC (same dosis/schedule of active arm)+ LPV 200mg combined with rtv 50 mg, 2 pills BID
Study NCT04414930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-amphetamine
Description: Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive amphetamine 5 mg po 1 hour prior to each training.
Study NCT04414930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive placebo po 1 hour prior to each training.
Study NCT00708981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multifactorial Intervention
Description: Study group will receive multifactorial intervention for advanced diabetic nephropathy:~Elements of multifactorial intervention:~1. BP control of \<130/80mmHg and renal protection with reduction of proteinuria to \<0.5g/day using therapy with ACE inhibitors and/or ARBs.~2. Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.~3. Use of hypolipidemic therapy to achieve targets of LDL \< 70 mg/dl, HDL > 40/50 mg/dl (M/F)and TG \< 200 mg/dl.~4. Patient enhanced self-management provided by combined diabetes-renal education curriculum.~5. Behavior and social intervention~6. Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators.
Study NCT04348461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells
Description: Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg
Study NCT04134936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) in addition to R-CHOP
Study NCT04134936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab plus lenalidomide
Description: Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) plus lenalidomide (starting dose 25 mg orally, on Day 1-10) in addition to R-CHOP
Study NCT02787460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Text Messages
Study NCT00130676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: daily for 7 days
Study NCT00130676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: daily for 7 days
Study NCT01785407 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement (Ferrous Sulfate Dried)
Description: Iron supplements of varying concentration will be administered to the four groups in the study. Iron bioavailability from the supplements will be assessed.
Study NCT04406610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2 CAR-T immunotherapy
Description: Antigen-specific T cell therapy
Study NCT00752037 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lopinavir/ritonavir and raltegravir
Description: lopinavir/ritonavir 400/100 mg po b.id. in combination with raltegravir 400 mg po b.i.d.
Study NCT03241615 — intervention group
Intervention type: OTHER
Intervention: Dysphagia evaluation
Description: Dysphagia evaluation is performed in a clinical setting by an eating assessment tool. Swallowing related quality of life is also assessed.
Study NCT00417287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PX-12
Description: 3 hour intravenous infusion as a dose of either 54 mg/m2 or 128 mg/m2 daily for 5 days every three weeks.
Study NCT01641510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Loading with prasugrel 30 mg followed by daily administration of prasugrel 5 mg
Study NCT01641510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Loading with clopidogrel 600 mg followed by daily administration of clopidogrel 75 mg
Study NCT02370342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Laparoscopic Surgery
Description: Undergo robot-assisted laparoscopic HIFU ablation
Study NCT02370342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound Ablation
Description: Undergo robot-assisted laparoscopic HIFU ablation
Study NCT02370342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Laparoscopic Surgery
Description: Undergo laparoscopic partial nephrectomy
Study NCT02370342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonatherm 600i Ultrasonic Lesion Generating System
Description: Device used for high-intensity focused ultrasound ablation
Study NCT01040026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with in vitro expanded haploidentical NK cells
Description: 10 expanded NK-DLI will be applied at fixed intervals and to each patient within 30 days (3 applications per week, Mo/We/Fr) starting with increasing CD56+CD3- NK cell doses at 3 dose levels (1.5x10e6/kg, 1.5x10e7/kg and 1x10e8/kg) and, if safe, continuing with maximally 7 doses of 1x10e8/kg. Maximal cumulative T-cell dose is fixed at \<1x10e5/kg
Study NCT02793050 — intervention group
Intervention type: DRUG
Intervention: Trabectedin
Description: Collection of data on the clinical use of Trabectedin
Study NCT00935298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation. After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5\*1/\*1 type and CYP3A5\*1/\*3 type administer 0.15mg/kg/d，CYP3A5\*3/\*3 type administer 0.08mg/kg/d).
Study NCT00622206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir and saquinavir
Description: saquinavir/ritonavir 1500/100 mg or 1500/50 mg Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
Study NCT04248452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT02438657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: median nerve block
Study NCT04248452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO
Study NCT03588871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental bleaching with PaintOn Plus VivaStyle
Description: Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent)
Study NCT03588871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental Bleaching impact in quality of life with PaintOn Plus Vivastyle
Description: Evaluation of oral quality of life after dental bleaching treatment with PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
Study NCT03588871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental bleaching with Opalescence GO
Description: Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence GO 6% HP (Ultradent)
Study NCT03588871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental Bleaching impact in quality of life with Opalescence GO
Description: Evaluation of oral quality of life after dental bleaching treatment with Opalescence GO 6% HP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
Study NCT03588871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental bleaching with Opalescence PF
Description: Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence PF 16% CP (Ultradent)
Study NCT04248452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT04248452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study NCT04248452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT04248452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Given IV
Study NCT04248452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT04248452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT04248452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT04248452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV
Study NCT04248452 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04500821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activator LFD-2100
Description: LipiFlow treatment with the Activators LFD-2100 will be performed on both eyes with MGD
Study NCT04464538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WALC-R
Description: Initial group education session and individualized coaching (remote)
Study NCT04464538 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Information leaflet
Description: Participants in the control group will complete baseline measures, and then they will receive written information on the benefits of increasing activity levels. This advice will be given in accordance with NHS guide on physical health.
Study NCT02392728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Virtual Reality (VR)
Description: Patients in this group will experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller. Following a resting period the patients will then experience the guided imagery session (e.g. visual images of pleasant scenery)
Study NCT02392728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (VR)
Description: Patients in this group will experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller. Following a resting period the patients will then experience the guided imagery session (e.g. visual images of pleasant scenery)
Study NCT02392728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Imagery
Description: Patients in this group will experience the guided imagery (e.g. visual images of pleasant scenery). Following a resting period the patients will then experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller
Study NCT02392728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: Patients in this group will experience the guided imagery (e.g. visual images of pleasant scenery). Following a resting period the patients will then experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller
Study NCT03014505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: Fecal Microbiota Transplantation and the traditional treatments for Decompensated Cirrhosis in part 1